Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
| Brand name | ERYTHROMYCIN |
| Generic name | ERYTHROMYCIN |
| Active ingredient(s) | ERYTHROMYCIN |
| Distributed by / for | Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; (NDC 70710-1048-3) |
| NDC | 70710-1048-3 |
| Full product label | Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; (NDC 70710-1048-3). |
| Recalling firm | Zydus Pharmaceuticals (USA) Inc |
| Distribution | Nationwide within the U.S |
| Quantity | 10,992 bottles |
| Recall initiated | 2026-04-29 |
| Report date | 2026-05-27 |
| Recall completed | — |
| Recall number | D-0545-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Pennington NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗